961 results on '"Vassilakopoulos, Theodoros P."'
Search Results
2. Leukemic form of high-grade B-cell lymphoma (HGBL) in a very elderly patient with multiple comorbidities: effective treatment of a very rare subtype with a mini-R-da-EPOCH version
3. How Early Can Checkpoint Inhibitors Induce a Complete Metabolic Response in Chemorefractory Hodgkin Lymphoma?
4. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
5. Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries
6. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
7. The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications
8. Cerebral venous sinus thrombosis in the setting of COVID-19 vaccination: a systematic review and meta-analysis
9. Real world data on the prognostic significance of monocytopenia in myelodysplastic syndrome
10. Toward a paradigm shift in prognostication and treatment of early‐stage Hodgkin lymphoma.
11. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes
12. A Nationwide Study of the Delayed Diagnosis and the Clinical Manifestations of Predominantly Antibody Deficiencies and CTLA4-Mediated Immune Dysregulation Syndrome in Greece
13. Thrombocytosis
14. Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature
15. H10: Long-Term Results Could Be Misleading Without an Updated Reading Key for Positron Emission Tomography
16. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome
17. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies
18. Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
19. Modulation of IL-6/STAT3 signaling axis in CD4+FOXP3− T cells represents a potential antitumor mechanism of azacitidine
20. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma : Pathogenesis and Patient Outcomes
21. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
22. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
23. Genetic Characterization of Primary Mediastinal B-Cell Lymphoma: Pathogenesis and Patient Outcomes
24. How to ventilate obstructive and asthmatic patients
25. What’s new about pulmonary hyperinflation in mechanically ventilated critical patients
26. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
27. The Role of 18FDG-PET/CT in Malignant Lymphomas: Clinical Implications
28. Malignant Lymphomas Introduction
29. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
30. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
31. The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
32. Indirect treatment comparisons of mosunetuzumab with third- and later-line treatments for relapsed/refractory follicular lymphoma
33. Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?
34. Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome
35. The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece
36. Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
37. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma
38. A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity
39. Prolonged 3-year spontaneous remission of diffuse large B-cell lymphoma upon withdrawal of infliximab and late relapse in a patient with psoriasis: a case report and review of the literature
40. Aggressive B-Cell Lymphomas
41. PET/CT in Hodgkin Lymphoma
42. An Overview of the Clinical Evaluation of Lymphomas According to the WHO 2008 Classification
43. Treatment of splenic marginal zone lymphoma
44. Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective
45. Prognostic Impact of Serum β 2 -Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients.
46. Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization
47. Supplementary Table S1 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
48. Supplementary Methods from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
49. Data from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
50. Supplementary Figure S2 from The Stat3/5 Signaling Biosignature in Hematopoietic Stem/Progenitor Cells Predicts Response and Outcome in Myelodysplastic Syndrome Patients Treated with Azacitidine
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.